Abselion has appointed Dale Gordon as chair as the company expands its commercial and international activities.

The Cambridge-based life sciences technology company said the move follows the establishment of its US subsidiary and reflects a shift towards commercial execution and growth.

Dale brings more than 30 years of experience across bioprocessing and life sciences leadership. He most recently served as chief executive officer at Mirus Bio and has also held senior roles at Cytiva and Merck Millipore.

The appointment comes as Abselion looks to scale adoption of its protein quantification technology across biotech and pharma workflows, particularly in biologics development and manufacturing.

Ruizhi Wang, chief executive officer and founder of Abselion, said: “Dale is renowned for his expertise in bioprocessing and strategic leadership. His appointment will strengthen our ability to make clear, confident decisions as we continue to build the business for long-term impact.”

He added: “Dale joins us at a point where the company is moving from early momentum into a more execution-focused phase, with growing commercial engagement and increasing international activity.”

Dale replaces Simon Douglas, who is stepping down after more than four years in the role.

He said: “Abselion has built strong scientific foundations alongside a clear focus on addressing practical challenges in cell and gene therapy and biopharma development and production workflows.”

He added: “I see a significant opportunity in how the company is translating that work into real-world use.”

Abselion’s emphasis on governance and board-level experience suggests a focus on structuring the business for growth rather than a near-term product or clinical milestone.